Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Michael Kreuter, David J. Lederer, Vincent Cottin, Nicolas Kahn, Brett Ley, Carlo Vancheri, Derek Weycker, Mark Atwood, Klaus-Uwe Kirchgaessler, Christopher J. Ryerson. Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019

Member's Comments

No comment yet.

Related content which might interest you: Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Comparison of clinical characteristics and prognosis in patients with idiopathic pulmonary upper lobe predominant pulmonary fibrosis and idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient Source: Eur Respir Rev 2011; 20: 114-117 Year: 2011 Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017 Year: 2017 Evaluating disease severity in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017 Year: 2017 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations Source: Eur Respir J 2016; 47: 344-345 Year: 2016